MicroRNAs Regulating Renin–Angiotensin–Aldosterone System, Sympathetic Nervous System and Left Ventricular Hypertrophy in Systemic Arterial Hypertension

Improta-Caria, Alex Cleber; Aras, Marcela Gordilho; Nascimento, Luca; Sousa, Ricardo Augusto Leoni De; Aras-Júnior, Roque; Souza, Bruno Solano de Freitas

doi:10.3390/biom11121771

Cited by 21 publications

(8 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, abnormal lipid metabolism leading to left ventricular hypertrophy was explained by the accumulation of lipids in or around myocytes. A study on the human heart showed that fat deposition in the left ventricle constituted a direct risk of myocardial hypertrophy 34 ; abnormal lipid metabolism can be manifested by strong systemic or local inflammation and mitochondrial oxidative stress 35 and/or increased production of reactive oxygen species in NADPH oxidase complex, resulting in oxidative modification of LDL, thereby amplifying the inflammatory potential 36 ; abnormal lipid metabolism was usually accompanied by insulin resistance in the animal model of high‐fat feeding 37 and promoted LVH 38 ; neurohumoral effects 39 included the effects of the sympathetic nervous system, 9 renal angiotensin aldosterone system (RAAS), and other hormones. In addition, other signaling pathways caused by dyslipidemia also played important roles in the development of myocardial hypertrophy.…”

Section: Discussionmentioning

confidence: 99%

Combined superposition effect of hypertension and dyslipidemia on left ventricular hypertrophy

Zhang

Shi

et al. 2022

Anim Models and Exp Med

View full text Add to dashboard Cite

Background Hypertension and dyslipidemia are considered reversible risk factors for cardiovascular disease. The purpose of this study was to explore the impact of traditional and nontraditional blood lipid profiles on the risk of left ventricular hypertrophy (LVH) and to explore the superposition effect of dyslipidemia combined with hypertension. Methods Data on 9134 participants (53.5 ± 10.3 years old) from the Northeast China Rural Cardiovascular Health Study (NCRCHS) were statistically analyzed. The blood lipid profile was measured by total cholesterol (TC), low‐density lipoprotein cholesterol (LDL‐C), high‐density lipoprotein cholesterol (HDL‐C), total glyceride (TG), and calculated nontraditional blood lipid indices including non‐HDL‐C, atherosclerosis index (AI), TC/HDL‐C, and residual cholesterol (RC). Results After the adjustment of age and gender, the odds ratios (ORs) of LVH in patients with hypertension, high LDL‐C, high non‐HDL‐C, high AI, and high TC/HDL‐C were 3.97 (3.31–4.76), 1.27 (1.02–1.59), 1.21 (1.04–1.39), 1.33 (1.15–1.53), and 1.42 (1.22–1.65), respectively. After full adjustment of potential confounding factors, high AI and TC/HDL‐C were associated with LVH rather than traditional blood lipid indices. The combination of hypertension and nontraditional dyslipidemia (defined by high AI and TC/HDL‐C) was associated with the highest risk of LVH, especially in participants under 45 years of age. The risk was more significant in men, 5.09‐fold and 6.24‐fold, respectively, compared with 3.66‐fold and 4.01‐fold in women. Conclusions People with dyslipidemia defined by nontraditional blood lipid indices (high AI and high TC/HDL‐C) and hypertension were more likely to develop LVH.

show abstract

Section: Discussionmentioning

confidence: 99%

Combined superposition effect of hypertension and dyslipidemia on left ventricular hypertrophy

Zhang

Shi

et al. 2022

Anim Models and Exp Med

View full text Add to dashboard Cite

show abstract

“…Several miRNAs regulate renin–angiotensin–aldosterone system genes. In addition, it is described that the miRNA expression is altered in hypertensive human patients [ 104 ]. MiR-136 was significantly downregulated in peripheral blood serum of hypertensive patients [ 105 ].…”

Section: Micrornas In the Diagnosis Of Cardiovascular Diseasesmentioning

confidence: 99%

Emerging Roles of Micrornas in Veterinary Cardiology

Reis-Ferreira

Neto-Mendes

Brás-Silva

et al. 2022

Veterinary Sciences

View full text Add to dashboard Cite

Over the last years, the importance of microRNAs (miRNAs) has increasingly been recognised. Each miRNA is a short sequence of non-coding RNA that influences countless genes’ expression and, thereby, contributes to several physiological pathways and diseases. It has been demonstrated that miRNAs participate in the development of many cardiovascular diseases (CVDs). This review synopsises the most recent studies emphasising miRNA’s influence in several CVDs affecting dogs and cats. It provides a concise outline of miRNA’s biology and function, the diagnostic potential of circulating miRNAs as biomarkers, and their role in different CVDs. It also discusses known and future roles for miRNAs as potential clinical biomarkers and therapeutic targets. So, this review gives a comprehensive outline of the most relevant miRNAs related to CVDs in Veterinary Medicine.

show abstract

“…Infection of the organism with a virus or parasite also modi es the expression of miRNAs, as in HIV [18] and Chagas disease [19,20]. Several miRNAs have been described deregulated in H [21][22][23], T2DM [24][25][26] and OB [27,28]. Among these, miRNA-1 (miR-1) [29], miRNA-21 (miR-21) [30] and miRNA-126 (miR-126) [31] have been highlighted.…”

Section: Introductionmentioning

confidence: 99%

Overexpression of miR-126-5p in the serum of patients with systemic arterial hypertension is correlated with creatinine and platelets

Improta-Caria,

Nonaka,

Aras

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Systemic arterial hypertension is a multicausal and multifactorial disease of high prevalence worldwide. The development, progression, and damage of target organs are associated not only with genetic and environmental factors, but also epigenetic factors, such as the regulation by microRNAs (miRNAs). MiRNAs – including miRNA-1-3p, miRNA-21-5p and miRNA-126-5p have been described as potential biomarkers in hypertension, type 2 diabetes and obesity, but their role of in the development and progression of the disease has been little explored. In the present study, we analyzed the expression of these three miRNAs in the serum of hypertensive, diabetic and obese patients compared with a healthy group and correlated with clinical and laboratory parameters. Methods:Using RT-qPCR, the expression of miRNA-1-3p, miRNA-21-5p and miRNA-126-5p was analyzed in the serum of 50 participants, control (n = 8), hypertensive only (n = 21), hypertensive in association with diabetes and obesity (n = 21). Results:The expression of miRNA-126-5p was significantly high in the hypertensive group when compared to the control group (p= 0.0170), however there was no statistical difference when compared to the hypertensive, diabetic and obese group. MiRNA-1-3p and miRNA-21-5p showed no statistical differences between groups. The correlation analysis showed a positive correlation of miRNA-126-5p with creatinine and a negative correlation with platelets. Conclusion: This study demonstrated that miRNA-126-5p is overexpressed in the serum of hypertensive patients, and may have a potential as a biomarker of early target kidney injury.

show abstract

MicroRNAs Regulating Renin–Angiotensin–Aldosterone System, Sympathetic Nervous System and Left Ventricular Hypertrophy in Systemic Arterial Hypertension

Cited by 21 publications

References 84 publications

Combined superposition effect of hypertension and dyslipidemia on left ventricular hypertrophy

Combined superposition effect of hypertension and dyslipidemia on left ventricular hypertrophy

Emerging Roles of Micrornas in Veterinary Cardiology

Overexpression of miR-126-5p in the serum of patients with systemic arterial hypertension is correlated with creatinine and platelets

Contact Info

Product

Resources

About